Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BVX-1021,BVX-0320
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Biovaxys
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BVX-1021 using a new batch of recombinant SARS-1 protein from the supplier that screened out the extraneous protein aggregate, has been synthesized using the purified SARS1 protein, OSU is now able to complete the neutralizing antibody studies.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 09, 2022
Lead Product(s) : BVX-1021,BVX-0320
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Biovaxys
Deal Size : Inapplicable
Deal Type : Inapplicable